ClinicalTrials.gov
ClinicalTrials.gov Menu

Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03427229
Recruitment Status : Completed
First Posted : February 9, 2018
Last Update Posted : February 9, 2018
Sponsor:
Information provided by (Responsible Party):
Giovanni Cammarota, Catholic University of the Sacred Heart

Brief Summary:

Fecal microbiota transplantation (FMT) is acknowledged as a highly effective treatment for recurrent Clostridium difficile infection (CDI). Usually single fecal infusion achieves satisfactory cure rates of recurrent CDI). However, several retrospective studies show that severe clinical picture of recurrent CDI is a risk factor for the failure of single-infusion FMT, suggesting that multiple fecal infusions are required to cure this condition.

This is an open-label randomized clinical trial aiming to assess if multiple-infusion FMT is more effective than single-infusion FMT in curing severe CDI


Condition or disease Intervention/treatment Phase
Clostridium Difficile Pseudomembranous Colitis Biological: Single-infusion FMT Drug: Vancomycin (before randomization) Biological: multiple-infusion FMT Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Clinical Trial: Single Versus Multiple-infusion Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
Actual Study Start Date : March 2016
Actual Primary Completion Date : October 30, 2017
Actual Study Completion Date : October 30, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement
Drug Information available for: Vancomycin

Arm Intervention/treatment
Experimental: Multiple-infusion FMT
Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
Drug: Vancomycin (before randomization)
Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.

Biological: multiple-infusion FMT
Patients will receive multiple fecal infusions by colonoscopy

Active Comparator: Single-infusion FMT
Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
Biological: Single-infusion FMT
Patients will receive a single fecal infusion by colonoscopy

Drug: Vancomycin (before randomization)
Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.




Primary Outcome Measures :
  1. Cure of C. difficile infection [ Time Frame: 8 weeks ]
    Disappearance of C. difficile-associated diarrhea



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Recurrent C. difficile infection (identified by positivity of C. difficile toxin in stools) with severe clinical picture (defined by the ESCMID Guidelines published in 2014 - Debast et al, Clin Microbiol Infect 2014)
  • Possibility to undergo standard antimicrobial therapy for recurrent C. difficile infection Approval of informed consent
  • Possibility to undergo protocol diagnostic and therapeutic procedures
  • Stool negativity for parasites
  • Stool negativity for Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic Escherichia coli and other microorganisms except for C. difficile
  • Blood negativity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL).

Exclusion Criteria:

  • Subjects <18 years old
  • Prior colectomy
  • Negativity of C. difficile toxin in stools
  • Mild clinical picture of C. difficile infection
  • High risk of post-colonoscopy complications
  • Other main gastrointestinal diseases (es. Crohn's disease or ulcerative colitis)
  • Stool positivity for parasites
  • Stool positivity for Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic Escherichia coli and other microorganisms except for C. difficile
  • Blood positivity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL).
  • Pregnancy or breastfeeding.
  • Inability to follow protocol procedures

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Giovanni Cammarota, Associate Professor of Gastroenterology, Catholic University of the Sacred Heart
ClinicalTrials.gov Identifier: NCT03427229     History of Changes
Other Study ID Numbers: 1206132017
First Posted: February 9, 2018    Key Record Dates
Last Update Posted: February 9, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Giovanni Cammarota, Catholic University of the Sacred Heart:
fecal microbiota transplantation
Clostridium difficile infection
pseudomembranous colitis

Additional relevant MeSH terms:
Infection
Colitis
Enterocolitis, Pseudomembranous
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Clostridium Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Enterocolitis
Vancomycin
Anti-Bacterial Agents
Anti-Infective Agents